The platform in discussion, an AI-powered SaaS known as Mealpen, is positioned to cater to the growing market of GLP-1 medication users seeking personalized nutritional support. GLP-1 medications like Ozempic and Wegovy have seen a surge in use, prompting a need for platforms offering tailored nutritional plans. Mealpen addresses this by providing personalized meal plans based on users' medication type, symptoms, and other related factors. Core features include AI-powered meal planning, symptom-based personalization, nutrition information, and smart shopping lists, operating on a freemium subscription model with Free, Plus, and Pro tiers. Mealpen, fully built and live, offers an acquisition opportunity for those interested in a ready-to-launch product in a growing market niche. The platform seeks to monetize through recurring revenue from subscriptions, with the potential for growth through targeted advertising, partnerships, SEO, and further feature development. Developed with expert consultation, the platform is fully owned by the seller, including complete website, application, and original source code, with a promise of 60 days' post-acquisition support for technical transition and development. The platform is at a stage ready for marketing and customer acquisition, yet to generate revenue. The current owner lacks the resources to grow the business and is open to offers from entrepreneurs and investors. This opportunity allows the new owner to skip the building phase and focus on marketing, expansion, and revenue growth within the GLP-1 user demographic.